


1. (Currently Amended) Compounds having the structure of Formula I:



Formula I

and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, or N-oxides, polymorphs, prodrugs, or metabolites, wherein Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, sulphur and nitrogen atoms, the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C₁-C₄), lower perhaloalkyl (C₁-C₄), cyano, hydroxy, nitro, halogen (e.g. F, Cl, Br, I), lower alkoxy (C₁-C₄), lower perhalo- alkoxy (C₁-C₄), unsubstituted amino, N-lower alkylamino (C₁-C₄) or N-lower alkylamino carbonyl (C₁-C₄);

R₁ represents a hydrogen, hydroxy, hydroxymethyl, amino, alkoxy, carbamoyl or halogen (e.g. fluorine, chlorine, bromine and iodine);

R₂ represents alkyl, C₃-C₇ cycloalkyl ring in which any 1-4 hydrogen atoms are substituted with halogen (e.g. F, Cl, Br, I), carbamoyl or lower alkyl;

W represents (CH₂)_p, where p represents 0 to 1;

X represents an oxygen, sulphur, NR or no atom wherein R represents hydrogen or C₁-C₆ alkyl;

Y represents CHR₅CO wherein R₅ represents hydrogen, methyl or (CH₂)_q wherein q represents 0 to 4;


R₃ represents hydrogen, lower alkyl or CO₂C(CH₃)₃;

R₆ and R₇ are independently selected from H, lower alkyl, COOH, CONH₂, NH₂, CH₂NH₂; and

26 R₄ represents C₁-C₁₅ saturated or unsaturated aliphatic hydrocarbon (straight chain or
27 branched) in which any 1 to 6 hydrogen atoms may be substituted with the group
28 independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or
29 heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of
30 nitrogen, oxygen and sulphur atoms with an option that any 1 to 3 hydrogen atoms on an
31 aryl or heteroaryl ring in said arylalkyl, arylalkenyl, heteroarylalkenyl group may be
32 substituted with lower alkyl (C₁-C₄), lower perhalo alkyl (C₁-C₄), cyano, hydroxy, nitro,
33 lower alkoxy, carbonyl, halogen, lower alkoxy (C₁-C₄), lower perhaloalkoxy (C₁-C₄),
34 unsubstituted amino, N-lower alkylamino (C₁-C₄), or N-lower alkylamino carbonyl (C₁-
35 C₄).


1 2. (Currently Amended) A compound according to claim 1 having the structure of
2 Formula II and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates,
3 ~~esters, enantiomers, diastereomers, or N-oxides, polymorphs, prodrugs, metabolites,~~
4 wherein

5 Ar, R₁, R₂, W, X, Y, R₃ and R₄ are as defined for formula I.




6
7
8
9 **Formula II**

1 3. (Currently Amended) A compound according to claim 1 having the structure of
2 Formula III and its pharmaceutically acceptable salts, pharmaceutically acceptable
3 ~~solvates, esters, enantiomers, diastereomers, or N-oxides, polymorphs, prodrugs,~~
4 ~~metabolites,~~ wherein Ar, R₁, R₂, R₃ and R₄ are as defined for Formula I.



6
7 **Formula III**

- 1 4. (Currently Amended) A compound according to claim 1 having the structure of
2 Formula IV and its pharmaceutically acceptable salts, ~~esters~~, enantiomers, diastereomers,
3 ~~or N-oxides, prodrugs, or metabolites~~ wherein R₃ and R₄ are as defined for Formula I, and
4 s represents 1 to 2, R₉ is H or F and R₁₀ is F.




- 5
- 1 5. (Currently Amended) A compound selected from the group consisting of
- 2 (2S)-(1 α , 5 α , 6 α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3-
- 3 oxocyclohexyl]-2-hydroxy-2-phenylacetamide;
- 4 (2S)-(1 α , 5 α , 6 α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or
- 5 3S)-3-(fluorocyclohexyl)-2-hydroxy-2-phenylacetamide;
- 6 (2S)-(1 α , 5 α , 6 α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or
- 7 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide;
- 8 (2S)-(1 α , 5 α , 6 α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-2[(1R or 1S)-3, 3-
- 9 difluorocyclohexyl]-2-hydroxy-2-phenylacetamide;
- 10 (2S)-(1 α , 5 α , 6 α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3,3-
- 11 difluorocyclopentyl]-2-hydroxy-2-phenylacetamide;
- 12 (2R)-(1 α , 5 α , 6 α)-6-N-[3-benzyl-3-azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3,3-
- 13 difluorocyclopentyl]-2-hydroxy-2-phenylacetamide;
- 14 (2S)-(1 α , 5 α , 6 α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-
- 15 azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3, 3-difluorocyclohexyl]-2-hydroxy-2-
- 16 phenylacetamide;

- 17 (2S)-(1 α , 5 α , 6 α)-6-N-[3-(2-(3, 4-methylenedioxyphenyl)ethyl)-3-
18 azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3, 3-difluorocyclopentyl]-2-hydroxy-2-
19 phenylacetamide;
- 20 (2R)-(1 α , 5 α , 6 α)-6-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-
21 azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S)-3, 3-difluorocyclopentyl]-2-hydroxy-2-
22 phenylacetamide;
- 23 (2S)-(1 α , 5 α , 6 α)-6-N-[3-(2-(3, 4-methylenedioxyphenyl)ethyl)-3-
24 azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-
25 2-phenylacetamide;
- 26 (2S)-(1 α , 5 α , 6 α)-6-N-[3-(2-(3, 4-methylenedioxyphenyl)ethyl)-3-
27 azabicyclo[3.1.0]-hexyl]-2-[(1R or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-
28 2-phenylacetamide;
- 29 (2S)-(1 α , 5 α , 6 α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R
30 or 1S)-3, 3-difluorocyclohexyl]-2-hydroxy-2-phenylacetamide;
- 31 (2S)-(1 α , 5 α , 6 α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R
32 or 1S)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide;
- 33 (2R)-(1 α , 5 α , 6 α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-
34 [(1R or 1S)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide;
- 35 (2S)-(1 α , 5 α , 6 α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R
36 or 1S, 3R or 3S)-3-fluorocyclohexyl]-2-hydroxy-2-phenylacetamide; and
- 37 (2S)-(1 α , 5 α , 6 α)-6-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hexyl]-2-[(1R
38 or 1S, 3R or 3S)-3-fluorocyclopentyl]-2-hydroxy-2-phenylacetamide.

- 1 6. (Currently Amended) A pharmaceutical composition comprising a therapeutically
2 effective amount of a compound as defined in any one of claims 1-5 together with
3 pharmaceutically acceptable carriers, excipients or diluents.

1 7. (Currently Amended) A method for treatment ~~or prophylaxis~~ of an animal or a
 2 human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal
 3 systems, wherein the disease or disorder is ~~mediated through muscarinic receptors~~ urinary
 4 incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive
 5 pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity,
 6 diabetes and gastrointestinal hyperkinesis, comprising administering to said animal or
 7 human, a therapeutically effective amount of a compound having the structure of Formula
 8 I,



12 Formula I

13 and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,
 14 enantiomers, diastereomers, or N-oxides, ~~polymorphs, prodrugs, metabolites~~, wherein
 15 Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group
 16 consisting of oxygen, sulphur and nitrogen atoms, the aryl or heteroaryl rings may be
 17 unsubstituted or substituted by one to three substituents independently selected from lower
 18 alkyl (C₁-C₄), lower perhaloalkyl (C₁-C₄), cyano, hydroxy, nitro, halogen (e.g. F, Cl, Br,
 19 I), lower alkoxy (C₁-C₄), lower perhalo- alkoxy (C₁-C₄), unsubstituted amino, N-lower
 20 alkylamino (C₁-C₄) or N-lower alkylamino carbonyl (C₁-C₄);

21 R₁ represents a hydrogen, hydroxy, hydroxymethyl, amino, alkoxy, carbamoyl or halogen
 22 (e.g. fluorine, chlorine, bromine and iodine);

23 R₂ represents alkyl, C₃-C₇ cycloalkyl ring in which any 1-4 hydrogen atoms are
 24 substituted with halogen (e.g. F, Cl, Br, I), carbamoyl or lower alkyl;

25 W represents (CH₂)_p, where p represents 0 to 1;

26 X represents an oxygen, sulphur, NR or no atom wherein R represents
 27 hydrogen or C₁-C₆ alkyl;

28 Y represents CHR_5CO wherein R_5 represents hydrogen, methyl or $(\text{CH}_2)_q$
29 wherein q represents 0 to 4;

30 R_3 represents hydrogen, lower alkyl or $\text{CO}_2\text{C}(\text{CH}_3)_3$;

31 R_6 and R_7 are independently selected from H, lower alkyl, COOH , CONH_2 , NH_2 ,
32 CH_2NH_2 ; and


33 R_4 represents $\text{C}_1\text{-C}_{15}$ saturated or unsaturated aliphatic hydrocarbon (straight chain or
34 branched) in which any 1 to 6 hydrogen atoms may be substituted with the group
35 independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or
36 heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of
37 nitrogen, oxygen and sulphur atoms with an option that any 1 to 3 hydrogen atoms on an
38 aryl or heteroaryl ring in said arylalkyl, arylalkenyl, heteroarylalkenyl group may be
39 substituted with lower alkyl ($\text{C}_1\text{-C}_4$), lower perhalo alkyl ($\text{C}_1\text{-C}_4$), cyano, hydroxy, nitro,
40 lower alkoxy, carbonyl, halogen, lower alkoxy ($\text{C}_1\text{-C}_4$), lower perhaloalkoxy ($\text{C}_1\text{-C}_4$),
41 unsubstituted amino, N-lower alkylamino ($\text{C}_1\text{-C}_4$), N-lower alkylamino carbonyl ($\text{C}_1\text{-C}_4$).

1 8. (Currently Amended) The method according to claim 7 for treatment or
2 prophylaxis of an animal or a human suffering from a disease or disorder of the
3 respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is
4 mediated through muscarinic receptors urinary incontinence, lower urinary tract symptoms
5 (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary
6 fibrosis, irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis,
7 comprising administering to said animal or human, a therapeutically effective amount of a
8 compound having the structure of Formula II and its pharmaceutically acceptable salts,
9 pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, or N-oxides,
10 polymorphs, prodrugs or metabolites, wherein Ar, R_1 , R_2 , W, X, Y, R_3 and R_4 are as
11 defined for Formula I.

12


13

14



Formula II


9. (Currently Amended) The method according to claim 7 for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis, comprising administering to said animal or human, a therapeutically effective amount of a compound having the structure of Formula III and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, or N-oxides, polymorphs, prodrugs or metabolites, wherein Ar, R₁, R₂, R₃ and R₄ are as defined for Formula I.



Formula - III

10. (Currently Amended) The method according to claim 7 for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis, comprising administering to said animal or human, a therapeutically effective amount of a compound having the structure of Formula-IV and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, or N-oxides,

10 ~~polymorphs, prodrugs or metabolites~~, wherein R₃ and R₄ are as defined for Formula I, s
 11 represents 1 to 2, R₉=H or F, and R₁₀=F.




12

1 11.- 14. (Cancelled)

1 15. (Currently Amended) The method for treatment ~~or prophylaxis~~ of an animal or a
 2 human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal
 3 systems, wherein the disease or disorder is mediated through muscarinic receptors,
 4 comprising administering to said animal or human, a therapeutically effective amount of
 5 the pharmaceutical composition according to claim 6.

1 16. (Original) The method according to claim 15 wherein the disease or disorder is
 2 urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic
 3 obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome,
 4 obesity, diabetes and gastrointestinal hyperkinesis.

1 17. (Currently Amended) A process of preparing compounds of Formula I,




Formula I


6 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, ~~esters~~,
 7 enantiomers, diastereomers, or N-oxides, ~~polymorphs, prodrugs or metabolites~~, wherein

- 8 Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group
9 consisting of oxygen, sulphur and nitrogen atoms, the aryl or heteroaryl rings may be
10 unsubstituted or substituted by one to three substituents independently selected from lower
11 alkyl (C₁-C₄), lower perhaloalkyl (C₁-C₄), cyano, hydroxy, nitro, halogen (e.g. F, Cl, Br,
12 I), lower alkoxy (C₁-C₄), lower perhalo- alkoxy (C₁-C₄), unsubstituted amino, N-lower
13 alkylamino (C₁-C₄) or N-lower alkylamino carbonyl (C₁-C₄);
- 14 R₁ represents a hydrogen, hydroxy, hydroxymethyl, amino, alkoxy, carbamoyl or
15 halogen (e.g. fluorine, chlorine, bromine and iodine);
- 16 R₂ represents alkyl, C₃-C₇ cycloalkyl ring in which any 1-4 hydrogen atoms are
17 substituted with halogen (e.g. F, Cl, Br, I), carbamoyl or lower alkyl;
- 18 W represents (CH₂)_p, where p represents 0 to 1;
- 19 X represents an oxygen, sulphur, NR or no atom wherein R represents
20 hydrogen or C₁-C₆ alkyl;
- 21 Y represents CHR₅CO wherein R₅ represents hydrogen, methyl or (CH₂)_q
22 wherein q represents 0 to 4;
- 23 R₃ represents hydrogen, lower alkyl or CO₂C(CH₃)₃;
- 24 R₆ and R₇ are independently selected from H, lower alkyl, COOH, CONH₂, NH₂,
25 CH₂NH₂; and
- 26 R₄ represents C₁-C₁₅ saturated or unsaturated aliphatic hydrocarbon (straight chain or
27 branched) in which any 1 to 6 hydrogen atoms may be substituted with the group
28 independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or
29 heteroarylalkenyl having 1 to 2 hetero atoms selected from the group consisting of
30 nitrogen, oxygen and sulphur atoms with an option that any 1 to 3 hydrogen atoms on an
31 aryl or heteroaryl ring in said arylalkyl, arylalkenyl, heteroarylalkenyl group may be
32 substituted with lower alkyl (C₁-C₄), lower perhalo alkyl (C₁-C₄), cyano, hydroxy, nitro,
33 lower alkoxycarbonyl, halogen, lower alkoxy (C₁-C₄), lower perhaloalkoxy (C₁-C₄),
34 unsubstituted amino, N-lower alkylamino (C₁-C₄), N-lower alkylamino carbonyl (C₁-C₄),
35 comprising

(a) condensing a compound of Formula VI with a compound of Formula V




Formula VI




Formula V

wherein Ar, R₁, R₂, W, X, Y, R₃, R₆ and R₇ are as defined earlier for Formula I, to give a protected compound of Formula VII wherein Ar, R₁, R₂, W, X, Y, R₃, R₆ and R₇ are as defined earlier and P is a protecting group for an amino group,



Formula VII

deprotecting the compound of Formula VII in the presence of a deprotecting agent to give an unprotected compound of Formula VIII wherein Ar, R₁, R₂, R₃, W, X, Y, R₆ and R₇ are as defined earlier, and




Formula VIII

(b) N-alkylated or benzylated the compound of Formula VIII with a suitable alkylating or benzylating agent to give compounds of Formula I wherein Ar, R₁, R₂, W, X, Y, R₃, R₄, R₆ and R₇ are as defined earlier.



1 18. – 26. (Cancelled).

1 27. (Currently Amended) A process of preparing compounds of Formula IV,




2
 3 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,
 4 enantiomers, diastereomers, or N-oxides, ~~polymorphs, prodrugs, or metabolites~~, wherein
 5 R₃ represents hydrogen, lower alkyl or CO₂C(CH₃)₃; R₄ represents C₁-C₁₅ saturated or
 6 unsaturated aliphatic hydrocarbon (straight chain or branched) in which any 1 to 6
 7 hydrogen atoms may be substituted with the group independently selected from halogen,
 8 arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl having 1 to 2 hetero atoms
 9 selected from the group consisting of nitrogen, oxygen and sulphur atoms with an option
 10 that any 1 to 3 hydrogen atoms on an aryl or heteroaryl ring in said arylalkyl, arylalkenyl,
 11 heteroarylalkenyl group may be substituted with lower alkyl (C₁-C₄), lower perhalo alkyl
 12 (C₁-C₄), cyano, hydroxy, nitro, lower alkoxy carbonyl, halogen, lower alkoxy (C₁-C₄),
 13 lower perhaloalkoxy (C₁-C₄), unsubstituted amino, N-lower alkylamino (C₁-C₄), N-lower
 14 alkylamino carbonyl (C₁-C₄); s represents 1 to 2, R₉ is H or F and R₁₀ is F, comprising

15 (a) condensing a compound of Formula IX with a compound of Formula X




wherein R_3 and R_4 are as defined earlier for Formula I, s represents 1 to 2, R_9 is H or F and R_{10} is F, to give a protected compound of Formula XI wherein R_3 , R_4 , s , R_9 and R_{10} are as defined earlier and P is a protecting group for an amino group,



Formula XI

(b) deprotecting the compound of Formula XI in the presence of a deprotecting agent to give an unprotected compound of Formula XII wherein R_3 , R_4 , s , R_9 and R_{10} are as defined earlier, and



Formula XII

(c) N-alkylated or benzylated the compound of Formula XII with a suitable alkylating or benzylating agent to give compounds of Formula IV wherein R_3 , R_4 , s , R_9 and R_{10} are as defined earlier.

28. – 36. (Cancelled).